AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 DEC 1 - (NewsRx.com & NewsRx.net) -- The susceptibility of tumors to innate and adaptive immunotherapy changes during tumor maturation.
"Immunotherapy of tumors using T cells expanded in vitro has met with mixed clinical success suggesting that a greater understanding of tumor/T-cell interaction is required. We used a HPV16E7 oncoprotein-based mouse tumor model to study this further. In this study, we demonstrate that a HPV16E7 tumor passes through at least three stages of immune susceptibility over time. At the earliest time point, infusion of intravenous immune cells fails to control tumor growth although the same cells given subcutaneously at the tumor site are effective," scientists in Australia report.
"In a second stage, the tumor becomes resistant to subcutaneous infusion of cells but is now susceptible to both adjuvant activated and HPV16E7-specific immune cells transferred intravenously," stated Trina J. Stewart and colleagues at the University of Queensland. "In the last phase, the tumor is susceptible to intravenous transfer of HPV16E7-specific cells, but not adjuvant-activated immune cells. The requirement for IFN-gamma ...
Source: HighBeam Research, Susceptibility of tumors to immunotherapy changes during maturation.